• 1
    Srinivasan J, Richens A., A risk-benefit assessment of vigabatrin in the treatment of neurological disorders. Drug Safety 1994;5:395405.
  • 2
    Elke T, Talbot JF, Lawden MC, Severe persistent visual field constriction associated with vigabatrin [Letter], Br Med J 1997;314:1801.
  • 3
    Wilson EA, Brodie MJ, Severe persistent visual field constriction associated with vigabatrin [Letter], Br Med J 1997;314:1693.
  • 4
    Wong IC, Mawer GE, Sander JW, Severe persistent visual field constriction associated with vigabatrin [letter]. Br Med J 1997;314:16934.
  • 5
    Blackwell N, Hayllar J, Kelly G., Severe persistent visual field constriction associated with vigabatrin [Letter]. Br Med J 1997;314:1694.
  • 6
    Harding GF, Severe persistent visual field constriction associated with vigabatrin [Letter], Br Med J 1997;314:1694.
  • 7
    Krauss GL, Johnson MA, Miller NR, Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:6148.
  • 8
    Arezzo JC, Schroeder CE, Litwak MS, Steward DL, Effects of vigabatrin on evoked potentials in dogs. Br J Clin Pharmacol 1989;27:53S60S.
  • 9
    Butler WH, Ford GP, Newberne JW, A study of the effects of vigabatrin on the central nervous system and retina of Sprague-Dawley and Lister-hooded rats. Toxicol Pathol 1987;15:1438.
  • 10
    Butler WH, The neuropathology of vigabatrin. Epilepsia 1989;30(suppl 3):S157.
  • 11
    Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH, Newberne JW, Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:22538.
  • 12
    Graham D., Neuropathology of vigabatrin. Br J Clin Pharmacol 1989;27:43S5S.
  • 13
    Hauw J-J, Trottier S, Boutry J-M, Sun P, Sazdovitch V, Duyckaerts C., The neuropathology of vigabatrin. Br J Clin Pract 1988;61:103.
  • 14
    Jackson GD, Williams SR, Weller RO, et al. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res 1994;18:5766.
  • 15
    Schroeder CE, Gibson JP, Yarrington J, Heydorn WE, Sussman NM, Arezzo JC, Effects of high-dose γ-vinyl GABA (vigabatrin) administration on visual and somatosensory evoked potentials in dogs. Epilepsia 1992;33(suppl 5):S1325.
  • 16
    Weiss KL, Schroeder CE, Kastin SJ, et al. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology 1994;44:19449.
  • 17
    Yarrington JT, Gibson JP, Dillberger JE, et al. Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1993;21:4809.
  • 18
    Jung MJ, Lippert B, Metcalf BW, γ-Vinyl GABA (4-amino-hex-5-enoic acid): a new selective irreversible inhibitor of GABA-T. J Neurochem 1977;29:797802.
  • 19
    Lippert B, Metcalf BW, Jung MJ, Casara P., 4-amino-hex-5-enoic-acid, a selective catalytic inhibitor of 4-aminobutyric acid transferase in mammalian brain. Eur J Biochem 1977;74:4415.
  • 20
    Meldrum M, Horton R., Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA transaminase, γ-acetylenic GABA (4-amino-hex-5-enoic acid) and γ-vinyl GABA (4-amino-hex-5-enoic acid). Psychopharmacology 1987;59:4750.
  • 21
    Myslobodsky MS, Ackerman RF, Engel J., Effects of γ-vinyl GABA on metrazol-activated and kindled seizures. Pharm Biochem Behav 1979;11:26571.
  • 22
    Palfreyman MG, Schechter PJ, Buckett WR, Tell GP, Koch-Weser J., The pharmacology of GABA-transaminase inhibitors. Biochem Pharmacol 1981;30:81724.
  • 23
    Schechter PJ, Tranier Y, Jung MJ, Bohlen P., Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of γ-acetylinic GABA and γ-vinyl GABA, two irreversible GABA-T inhibitors. Eur J Pharmacol 1977;45:31928.
  • 24
    Browne TR, Mattson RH, Penry JK, et al. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology 1987;37:1849.
  • 25
    Browne TR, Mattson RH, Penry JK, A multicenter study of vigabatrin for drug-resistant epilepsy. Br J Clin Pharmacol 1989;27:95S100S.
  • 26
    Browne TR, Mattson RH, Penry JK, et al. Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures: an update. Neurology 1991;41:3634.
  • 27
    French JA, Mosier M, Walker S, Sommerville K, Sussman N., the Vigabatrin Protocol 024 Investigative Cohort. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 1996;46:5461.
  • 28
    Gram L, Klosterkov P, Dam M., Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol 1985;17:2626.
  • 29
    Guberman A, Bruni J, DesForges C., Vigabatrin in uncontrolled complex partial seizures in adult patients with epilepsy: double-blind, placebo-controlled, dose-ranging study. Can J Neurol Sci 1994;21(suppl 2):S178.
  • 30
    Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ, Vigabatrin vs. carbamazepine monotherapy in patients with newly diagnosed epilepsy: a randomized, controlled study. Arch Neurol 1995;52:98996.
  • 31
    Loiseau P, Pardenberg JP, Pestre M, Guyot M, Schechter PJ, Tell GP, Double-blind placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia 1986;27:11520.
  • 32
    Mumford JP, Dam M., Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989;27(suppl 1):101S7S.
  • 33
    Reynolds EH, Ring HA, Farr IN, Open, double-blind and long-term study of vigabatrin in chronic epilepsy. Epilepsia 1991;32:5208.
  • 34
    Rimmer EM, Richens A., Double-blind study of γ-vinyl GABA in patients with refractory epilepsy. Lancet 1984;1:18990.
  • 35
    Tartara A, Manni R, Galemberti CA, Hardenberg J, Orwin J, Perucca E., Vigabatrin in the treatment of epilepsy: a double-blind placebo-controlled study. Epilepsia 1986;27:71723.
  • 36
    Tassinari CA, Michelucci R, Ambrosetto G, Salvi F., Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch Neurol 1987;44:90710.
  • 37
    Hauw JJ, Boutry JM, Sun P, Sazdovitch V, Duyckaerts C., Effects of vigabatrin and GABA on myelinated rat cerebellar cultures: preliminary data. Br J Clin Pharmacol 1989;27:47S52S.
  • 38
    John RA, Rimmer EM, Williams J, Cole G, Fowler LJ, Richens A., Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors: comparison of effects of ethanol-amine-O-sulfate and vigabatrin. Biochem Pharmacol 1987;36:146773.
  • 39
    Fowler L., Analysis of the major amino acids of rat brain after in vivo inhibition of transaminase by ethanolamine-O-sulfate. J Neurochem 1973;21:43740.
  • 40
    Jung MJ, Design, biochemistry and pharmacology of enzyme-activated irreversible inhibitors of GABA. In: BrodbeckU, ed. Enzyme inhibitors. Weinheim : Verlag Chemie; 1980:8595.
  • 41
    Ben-Menachem E, Persson LI, Schechter PJ, et al. The effect of different vigabatrin treatment regiment on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989;27(suppl 1):79S85S.
  • 42
    Tripier MF, Berard M, Toga M, Martin-Bouyer G, Le Breton R., Garat J., Experimental hexachlorophene encephalopathy in mice and baboons: light and electron microscopic study. Acta Neuropathol 1981;7:403.
  • 43
    Noel PR, Worden NA, Palmer AC, Neuropathologic effects and comparative toxicity for dogs of isonicotinic acid hydrazide and its methanosulfonate derivative. Toxicol Appl Pharmacol 1967;10:18398.
  • 44
    O'Shaughnessy DJ, Losos GJ, Peripheral and central nervous system lesions caused by triethyl- and trimethyl-tin salts in rats. Toxicol Pathol 1986;14:1418.
  • 45
    Dorman DC, Zachary JF, Buck WB, Neuropathologic findings of bromethalin toxicosis in the cat. Vet Pathol 1992;29:13944.
  • 46
    Albee RR, Mattson JL, Eisenbrandt DL, Evaluation of the flash evoked potentials in vigabatrin treated dogs. Hoechst Marion Roussel Internal Report, 1989.
  • 47
    Duncan JS, Jackson GD, Connelly A, et al. Investigation of effects of vigabatrin with magnetic resonance imaging and spectroscopy in vivo. In: ShorvonSD, ed. Magnetic resonance scanning and epilepsy. New York : Plenum Press, 1994:758.
  • 48
    Peyster RG, Sussman NM, Hershey BL, et al. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia 1995;36:93100.
  • 49
    Agosti R, Yasargil G, Egli M, Wieser HG, Wiestler OD, Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles. Epilepsy Res 1990;6:16670.
  • 50
    Ben-Menachem E, Nordborg C, Hedstrom A, Augustinsson LE, Silvenius H., Case report of surgical brain sample after 2 1/2 years of vigabatrin therapy [Abstract], Epilepsia 1988;29(suppl 5):699.
  • 51
    Bryant AE, Lopes MB, Bebin EM, Absence of intramyelinic edema in three patients treated with vigabatrin [Abstract]. Epilepsia 1994;35:115.
  • 52
    Cannon DJ, Butler WH, Mumford JP, Lewis PJ, Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neurol 1991;6(suppl 2):2S1724.
  • 53
    Cannon DJ, Weller RO, Mumford JP, No vigabatrin-induced microvacuolation in human brains: further neuropathological investigations [Abstract]. Epilepsia 1991;32(suppl 1):12.
  • 54
    Hammond EJ, Ballinger WE, Lu L, Wilder BJ, Uthman BM, Reid SA, Absence of cortical white matter changes in three patients undergoing long-term vigabatrin therapy. Epilepsy Res 1992;12:2615.
  • 55
    Paljarvi L, Vapalahti M, Sivenius J, Riekkinen P., Neuropathological findings in 5 patients with vigabatrin treatment [Abstract]. Neurology 1990;40(suppl 1):157.
  • 56
    Pedersen B, Hojgaard K, Dam M., Vigabatrin: no microvacuoles in a human brain. Epilepsy Res 1987;1:746.
  • 57
    Cosi V, Callieco R, Galimberti CA, Manni R, Tartare A, Perucca E., Evoked potentials during long-term vigabatrin treatment in patients with epilepsy. Clin Neurol Neurosurg 1987;89(suppl 1):1012.
  • 58
    Cosi V, Callieco R, Galimberti CA, et al. Effect of vigabatrin (gamma-vinyl-GABA) on visual, brainstem auditory and somato-sensory evoked potentials in epileptic patients. Eur Neurol 1988;28:426.
  • 59
    Cosi V, Callieco R, Galimberti CA, et al. Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol 1989;27:61S8S.
  • 60
    Hammond EJ, Wilder BJ, Effect of gamma-vinyl GABA on human pattern evoked visual potentials. Neurology 1985;35:18013.
  • 61
    Hammond EJ, Rangel RJ, Wilder BJ, Evoked potential monitoring of vigabatrin patients. Br J Clin Pract 1988;61:1623.
  • 62
    Liegeois-Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P., Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients. Br J Clin Pharmacol 1989;27:69S72S.
  • 63
    Mauguiere F, Chauvel P, Dewailly J, Dousse N., No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. Epilepsia 1997;38:3018.
  • 64
    Ylinen A, Sivenius J, Pitkanen A, et al. γ-Vinyl GABA (vigabatrin) in epilepsy: clinical, neurochemical, and neurophysiologic monitoring in epileptic patients. Epilepsia 1992;33:91722.
  • 65
    Cocito L, Maffini M, Loeb C., MRI findings in epileptic patients on vigabatrin for more than 5 years. Seizure 1992;1:1635.
  • 66
    Grunewald RA, Jackson GD, Connelly A, Duncan JS, Vigabatrin-related changes in human brain measured by quantitative MRI [Abstract]. Epilepsia 1993;34(suppl 6):97.
  • 67
    Hershey BL, Sommerville KW, Sussman NM, MRI scanning with vigabatrin therapy for focal epilepsy [Abstract]. Epilepsia 1993;34(suppl 6):67.
  • 68
    Jackson GD, Grunewald RA, Connelly A, Duncan JS, Vigabatrin related changes in the human brain measured by MRI and quantitation of T2 relaxation time [Abstract]. Seizure 1993;2:1601.
  • 69
    Jackson GD, Grunewald RA, Connelly A, Duncan JS, Quantitative MR relaxometry study of effects of vigabatrin on the brains of patients with epilepsy. Epilepsy Res 1994;18:12737.
  • 70
    Dodrill CB, Arnett JL, Sommerville KW, Sussman NM, Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology 1993;43:25017.
  • 71
    Dodrill CB, Arnett JL, Sommerville KW, Sussman NM, Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia 1995;36:16473.
  • 72
    Kalviainen R, Aikia M, Riekkinen PJ, Vigabatrin monotherapy in newly diagnosed patients with epilepsy: two-year comparative follow-up of efficacy, safety and cognitive effects [Abstract]. Epilepsia 1995;36(suppl 3):S105.
  • 73
    McGuire AM, Duncan JS, Trimble MR, Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy. Epilepsia 1992;33:12834.
  • 74
    Mumford JP, Cannon DJ, Vigabatrin. Epilepsia 1994;35(suppl 5):S258.
  • 75
    Ylinen A, Kalviainen R, Riekkinen PJ, Long-term efficacy and cognitive effects of vigabatrin. Acta Neurol Scand 1995;(suppl 162):4750.
  • 76
    Monaco F., Cognitive effects of vigabatrin: a review. Neurology 1996;47(suppl 1):S611.
  • 77
    Grunewald RA, Thompson PJ, Corcoran R, Corden Z, Jackson GD, Duncan JS, Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatry 1994;57:105763.
  • 78
    Mervaala E, Kalkiainen R, Kononen M, et al. Vigabatrin and car-bamazepine monotherapy do not impair cognitive functions in event-related potentials [Abstract]. Epilepsia 1993;34(suppl 6):95.